Cognitive impairment affects up to 65% of multiple sclerosis (MS) subjects, especially memory function.
Rothschild Foundation has developped the Paris Visual Learning and memory Test (PVLT). 165 healthy volunteers were studied for its normalization.
The main objective of the present study is to assess the validity of PVLT by comparing MS patients' test results to a database including the test results of 280 healthy control subjects, following recommended international standards.

开始日期2013-12-19

申办/合作机构

Fondation Ophtalmologique Adolphe de Rothschild

CTRI/2010/091/001358 / Recruiting临床1期IIT

An open labeled, comparative phase-2 study to assess the efficacy and safety of duodenal release prussian blue formulation for accelerated removal of radio-thallium from the body

开始日期2008-02-24

申办/合作机构-

100 项与普鲁士蓝相关的临床结果

登录后查看更多信息

100 项与普鲁士蓝相关的转化医学

登录后查看更多信息

100 项与普鲁士蓝相关的专利（医药）

登录后查看更多信息

311

项与普鲁士蓝相关的文献（医药）

2024-10-20·Nanomedicine

Photothermal therapy co-localized with CD137 agonism improves survival in an SM1 melanoma model without hepatotoxicity

Article

作者: Balakrishnan, Preethi Bala ; Fernandes, Rohan ; Chin, Samantha J ; Sweeney, Elizabeth E ; Ghofrani, Joshua ; Medina, Jacob A ; Ledezma, Debbie K ; Chen, Jie ; Lee, Norman H

Aim: We investigate combining Prussian Blue nanoparticles (PBNPs), as photothermal therapy (PTT) agents, with agonistic CD137 antibodies (αCD137) on a single nanoparticle platform to deliver non-toxic, anti-tumor efficacy in SM1 murine melanoma.Methods: We electrostatically coated PBNPs with αCD137 (αCD137-PBNPs) and quantified their physicochemical characteristics, photothermal and co-stimulatory capabilities. Next, we tested the efficacy and hepatotoxicity of PTT using αCD137-PBNPs (αCD137-PBNP-PTT) in SM1 tumor-bearing mice.Results: The αCD137-PBNPs retained both the photothermal and agonistic properties of the PBNPs and αCD137, respectively. In vivo, SM1 tumor-bearing mice treated with αCD137-PBNP-PTT exhibited a significantly higher survival rate (50%) without hepatotoxicity, compared with control treatments.Conclusion: These data suggest the potential utility of co-localizing PBNP-PTT with αCD137-based agonism as a novel combination nanomedicine.

2024-10-17·Small (Weinheim an der Bergstrasse, Germany)

A Bacterial Capturing, Neural Network-Like Carbon Nanotubes/Prussian Blue/Puerarin Nanocomposite for Microwave Treatment of Staphylococcus Aureus-Infected Osteomyelitis.

Article

作者: Cui, Zhenduo ; Liu, Hanpeng ; Jin, Liguo ; Liu, Xiangmei ; Zhang, Yu ; Li, Zhaoyang ; Wu, Shuilin ; Mao, Congyang ; Wang, Chaofeng ; Jiang, Hui ; Zheng, Yufeng ; Zhu, Shengli

Staphylococcus aureus (S. aureus)-infected osteomyelitis is a deep tissue infection that cannot be effectively treated with antibiotics. Microwave (MW) thermal therapy (MTT) and MW dynamic therapy (MDT) based on MW-responsive materials are promising for the therapy of bacteria-infected osteomyelitis occurring in deep tissues that cannot be effectively treated with antibiotics. In this work, the MW-responsive system of carbon nanotubes (CNTs)/Prussian blue (PB)/puerarin (Pue) with stable network-like structures is constructed. The PB is grown in situ on the CNTs, and its introduction not only reduces the aggregation of the network-like structures of the CNTs, but the large specific surface area and mesoporous structure can also provide many active sites for the adsorption of oxygen and polar molecules. Pue is a natural anti-inflammatory material that reduces inflammation at the infection site. The composite of the CNTs and PB avoids the skin effect and thus can improve dielectric and reflection losses. The MW thermal response of CNTs/PB/Pue is mainly due to the occurrence of reflection loss, dielectric loss, multiple reflections and scattering, interface polarization, and dipole polarization. In addition, under MW irradiation, the CNTs/PB/Pue can produce reactive oxygen species (ROS), such as singlet oxygen (¹O₂), hydroxyl radical (·OH).

2024-10-01·Journal of Medical Toxicology

Attempted Self-Harm with Elemental Thallium Purchased Online: Case Report with Analytical Confirmation

Article

作者: Spadaro, Anthony ; Calello, Diane P ; Lee, Andrew Sae Young ; Nelson, Lewis S ; Greller, Howard A. ; Greller, Howard A ; Ruck, Bruce ; Calello, Diane P. ; Nelson, Lewis S. ; Pineda, Hilda ; Parris, Mehruba A. ; Parris, Mehruba A

AbstractIntroductionThallium is a highly toxic metal, with most publications demonstrating poisoning from thallium salts. We report on a patient with elevated serum and urine thallium concentrations from an intentional ingestion of elemental thallium purchased from the internet for self-harm.Case ReportThe regional poison center was contacted about an 18-year-old man who ingested a fragment from a 100-gram bar reported to be elemental thallium. Serial serum and urine thallium concentrations were obtained. Prussian blue was started on hospital day (HD) 2. A metal fragment was seen on abdominal x-ray and removed via colonoscopy on HD3. The ingested fragment was analyzed via inductively coupled plasma mass spectrometry (ICP-MS) and found to be 87.0% elemental thallium. The initial serum thallium concentration obtained on HD1 was 423.5 mcg/L (reference range < 5.1 mcg/L), which subsequently decreased to 4.5 mcg/L, 29 days after the ingestion. An initial random urine thallium concentration obtained on HD 3 was 1850.5 mcg/g creatinine (reference range < 0.4 mcg/g creatinine). The patient remained hospitalized for 23 days and, when seen in follow-up, had not developed any signs or symptoms of thallium toxicity.DiscussionElemental thallium ingestion is a rare toxicologic exposure, with limited published clinical and analytical experience to guide management. This case report describes a patient with ingestion of elemental thallium who developed elevated serum and urine thallium concentrations and was treated with Prussian blue. Despite having elevated serum and urine thallium concentrations consistent with previous fatal exposures, more evidence is needed to understand the differences between elemental thallium and thallium salts.

项与普鲁士蓝相关的新闻（医药）

2024-06-11

·PRNewswire

Global Anti-Radiation Drugs Market to Register Incremental Growth at a CAGR of ~9% by 2030 | DelveInsight

The rise in demand for anti-radiation drugs is mainly driven by several factors. These include the growing occurrence of side effects linked to cancer screening methods, heightened risks of exposure to radiological or nuclear emergencies, and the increasing focus of nuclear-capable nations on safeguarding against radiation. These trends are expected to fuel the expansion of the anti-radiation drugs market from 2024 to 2030. LAS VEGAS, June 11, 2024 /PRNewswire/ -- DelveInsight's Anti-Radiation Drugs Market Insights report provides the current and forecast market analysis, individual leading anti-radiation drugs companies' market shares, challenges, anti-radiation drugs market drivers, barriers, trends, and key market anti-radiation drugs companies in the market. Key Takeaways from the Anti-Radiation Drugs Market Report As per DelveInsight estimates, North America is anticipated to dominate the global anti-radiation drugs market during the forecast period. In the compound type segment of the anti-radiation drugs market, the Potassium iodide sub-category had a significant revenue share in the year 2023. This can be ascribed to the various characteristics and advantages associated with potassium iodide. Notable anti-radiation drugs companies such as Novartis AG, Anbex Inc., Amgen Inc., Myelo Therapeutics, Arco Pharmaceuticals LLC, BTG International Inc., Cellphire Inc., Darnitsa, Enzychem Lifesciences Corporation, Humanetics Corporation, Mission Pharmacal Company, Chrysalis BioTherapeutics Inc., Pluri Inc., Partner Therapeutics, HEYL Chemisch-pharmazeutische Fabrik GmbH & Co. KG., RxBio Inc., Coherus Biosciences, Onconova Therapeutics, Jubilant Life Sciences, Soligenix Inc., and several others, are currently operating in the anti-radiation drugs market. In September 2023, the U.S. Department of Defense awarded Edina-based Humanetics a USD 20 million contract to develop a pill that prevents radiation damage in military members and first responders affected by events such as nuclear accidents, warfare, and dirty bombs. In May 2023, the first-in-human clinical trial of an experimental oral drug for removing radioactive contaminants from inside the body, testing the safety, tolerability, and processing in the body of escalating doses of the investigational drug product HOPO 14-1 was initiated in healthy adults. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, was funding the Phase 1 trial, which was sponsored and conducted by SRI International of Menlo Park, California. In March 2022, Novartis announced that the US Food and Drug Administration (FDA) approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for the treatment of adult patients with a certain type of advanced cancer called prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) that has spread to other parts of the body. These patients have already been treated with other anticancer treatments (androgen receptor pathway inhibition and taxane-based chemotherapy). To read more about the latest highlights related to the anti-radiation drugs market, get a snapshot of the key highlights entailed in the Global Anti-Radiation Drugs Market Report Anti-Radiation Drugs Overview Anti-radiation drugs are pharmaceutical compounds designed to mitigate the damaging effects of radiation exposure on the human body. These drugs work by either scavenging free radicals generated by radiation or by enhancing the repair mechanisms of cells damaged by radiation. One class of anti-radiation drugs includes radioprotectors, which are administered before radiation exposure to prevent or reduce its harmful effects. Another class, known as radiomitigators, is given after exposure to alleviate the severity of radiation-induced damage. These drugs hold significant promise in scenarios such as nuclear accidents, medical radiation therapy, and space travel, where the risk of radiation exposure is a concern. Research into anti-radiation drugs is ongoing, with scientists continually striving to improve their efficacy and minimize side effects. Some compounds under investigation show potential not only in protecting against acute radiation sickness but also in mitigating long-term effects such as cancer development. As our understanding of radiation biology advances, coupled with advancements in drug development technologies, the prospects for more effective and accessible anti-radiation drugs continue to brighten, offering hope for safer environments in radiation-prone situations. Anti-Radiation Drugs Market Insights In 2023, North America dominated the anti-radiation drugs market, primarily due to several factors contributing to growth. These include a substantial patient population afflicted with various illnesses like cancer, increasing numbers of diagnostic procedures, and governmental initiatives aimed at public health in the region. This trend is expected to continue from 2024 to 2030. The prevalence of cancer in the United States, for example, drives a significant demand for anti-radiation drugs. Statistics from the American Cancer Society projected around 2 million new cancer cases in the United States in 2024, leading to heightened demand for these drugs to support cancer diagnostic procedures. Additionally, the US benefits from a strong focus on clinical research and the presence of leading pharmaceutical companies, further bolstering the market for anti-radiation drugs. Moreover, in 2022, the US Department of Health and Human Services (HHS) allocated USD 290 million for the purchase of Nplate, a drug produced by Amgen USA Inc., intended to treat radiation sickness in the event of a nuclear emergency. This investment reflects ongoing efforts to enhance preparedness for radiological and nuclear emergencies and underscores the commitment to saving lives in such scenarios. To know more about why North America is leading the market growth in the anti-radiation drugs market, get a snapshot of the Anti-Radiation Drugs Market Outlook Anti-Radiation Drugs Market Dynamics The market dynamics of anti-radiation drugs are driven by a complex interplay of factors ranging from technological advancements to geopolitical events and regulatory frameworks. One of the primary drivers is the increasing threat of radiation exposure from various sources such as nuclear accidents, medical procedures, and potential radiological terrorism. This heightened awareness has propelled research and development efforts to create effective anti-radiation drugs that can mitigate the harmful effects of radiation exposure. Moreover, the growing prevalence of cancer and the widespread use of radiation therapy as a treatment modality has further fueled the demand for anti-radiation drugs. As more individuals undergo radiation-based treatments, there is a parallel need for medications that can protect healthy tissues and organs from the damaging effects of ionizing radiation. The competitive landscape of the anti-radiation drugs market is characterized by both established pharmaceutical companies and innovative startups vying for market share. Established players often leverage their resources and expertise to develop and commercialize new anti-radiation drugs, while startups focus on disruptive technologies and novel approaches to address unmet needs in radiation protection. Government initiatives and regulatory frameworks also play a crucial role in shaping the market dynamics of anti-radiation drugs. Regulatory agencies set standards for safety, efficacy, and quality assurance, which impact the development, approval, and commercialization of these medications. Additionally, government investments in research and development, as well as funding for procurement and stockpiling of anti-radiation drugs for emergency preparedness, influence market dynamics. Overall, the anti-radiation drugs market is characterized by a dynamic landscape driven by technological innovation, healthcare trends, regulatory factors, and geopolitical considerations. As the threat of radiation exposure continues to evolve, so too will the demand for effective anti-radiation drugs, driving further growth and innovation in this important sector of the pharmaceutical industry. Get a sneak peek at the anti-radiation drugs market dynamics @ Anti-Radiation Drugs Market Dynamics Analysis Anti-Radiation Drugs Market Assessment Anti-Radiation Drugs Market Segmentation Anti-Radiation Drugs Market Segmentation By Compound: Potassium Iodide, Prussian Blue, Diethylenetriamine Pentaacetic Acid, Colony Stimulating Factors, and Others Anti-Radiation Drugs Market Segmentation By Indication: Acute Radiation Syndrome, Cancer Treatment, and Others Anti-Radiation Drugs Market Segmentation By Radiation Type: Ionizing Radiations and Non-Ionizing Radiations Anti-Radiation Drugs Market Segmentation By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Others Anti-Radiation Drugs Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View Which MedTech key players in the anti-radiation drugs market are set to emerge as the trendsetter explore @ Anti-Radiation Drugs Companies Table of Contents Interested in knowing the anti-radiation drugs market by 2030? Click to get a snapshot of the Anti-Radiation Drugs Market Trends Related Reports Cancer Biomarkers Market Cancer Biomarkers Market Insight, Competitive Landscape, and Market Forecast – 2030 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key cancer biomarkers companies, including F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific, Inc., QIAGEN N.V., Illumina, Inc., Bio-Rad Laboratories, Inc., Abbott Laboratories, bioMérieux SA, BD, Merck Millipore, Agilent Technologies, Myriad Genetics, Sysmex Corporation, Hologic, Inc., Quest Diagnostics, Centogene N.V., PerkinElmer, Inc., Siemens Healthineers, Exact Sciences, R&D Systems, Inc., BioVision, Inc., among others. Cancer Therapy Market Cancer Therapy Market Insight, Competitive Landscape, and Market Forecast – 2030 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key cancer therapy companies, including GlaxoSmithKline, Eli Lilly & Company, F. Hoffmann-La Roche Ltd, AbbVie Inc., Amgen Inc, Sanofi, Merck & Co., Inc, Novartis AG, Pfizer Inc, AstraZeneca, Bristol Myers Squibb., Gilead Sciences, Inc., Janssen Global Services, LLC, Elekta AB, Varian Medical Systems, Inc., Accuray Incorporated, Pyrexar Medical, Eckert & Ziegler, IBA, Panacea Medical Technologies Pvt. Ltd., among others. Oncology Drugs Market Oncology Drugs Market Insight, Competitive Landscape, and Market Forecast – 2030 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key oncology drugs companies, including GlaxoSmithKline, Eli Lilly & Company, F. Hoffmann-La Roche Ltd, AbbVie Inc., Amgen Inc., Sanofi, Merck & Co., Inc, Novartis AG, Pfizer Inc, AstraZeneca, Bristol Myers Squibb., Gilead Sciences, Inc., Janssen Global Services, LLC, BAYER AG., Celldex Therapeutics Inc., Alaunos Therapeutics, Inc., Astellas Pharma Inc., Genentech, Inc., Sandoz International GmbH, BeiGene, among others. Liquid Biopsy in Cancer Diagnostics Market Liquid Biopsy in Cancer Diagnostics Market Insight, Competitive Landscape, and Market Forecast – 2030 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key liquid biopsy in cancer diagnostics companies, including Myriad Genetics Inc., Exact Sciences Corporation, Biocartis, Sysmex Corporation, Thermo Fisher Scientific Inc, Biocept Inc, Agilent Technologies Inc, MDx Health, Neogenomics Laboratories, F. Hoffman La Roche Ltd, Guardant Health, Bio-Techne, Illumina Inc, QIAGEN, Lucence Health Inc, Personal Gemone Diagnostics Inc, SAGA Diagnostics, Agena Bioscience Inc, The Menarini Group, MiRXES Pte Ltd., among others. About DelveInsight DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP

放射疗法

2023-11-07

·CPHI制药在线

生物膜仿生纳米制剂的研究进展（上）

关注并星标CPHI制药在线近年来，随着生物医学的发展，基于仿生技术的细胞膜介导的纳米药物递送系统，因其有机整合了天然生物膜的低免疫原性、肿瘤靶向性和智能纳米载体设计的可调控性、多功能性，成为纳米技术在肿瘤靶向治疗的一种有前景的递送策略。常见的生物膜仿生纳米制剂主要有肿瘤细胞膜、红细胞膜、血小板膜、白细胞膜、干细胞膜、细胞外囊泡（外泌体、微囊泡及凋亡小体）、内质网膜以及复合生物膜等。 1、肿瘤细胞膜仿生递药系统肿瘤细胞具有极强的增殖能力，体外培养即可大量获得，为相关研究奠定了物质基础。肿瘤细胞膜因其自身免疫逃逸的性质，能够延长纳米粒在血液中的循环时间，从而可提高药物治疗肿瘤的选择性积累。同时，肿瘤细胞膜上存在 N-钙黏素、TF-抗原等自身靶向识别分子，可使肿瘤细胞膜仿生递药系统获得良好的同源靶向性，实现对肿瘤的精准治疗。目前，各种肿瘤细胞膜纳米载体的研发和应用已成为当前诊断和治疗肿瘤的研究热点。研究发现，基于转移性癌细胞的同型聚集，将4T1 转移性乳腺癌细胞膜涂覆在载有紫杉醇的高分子聚合物纳米粒上，膜仿生纳米粒特异性的靶向乳腺癌细胞，在原发性肿瘤和转移性肺组织中的紫杉醇含量是未涂覆癌细胞膜的纳米粒的15倍。使用 4T1 乳腺癌细胞膜作为外壳对金纳米粒进行包被，制备了一种运载阿霉素的金纳米粒，该仿生纳米粒能结合癌细胞的免疫逃逸、同源靶向特性和金纳米粒子的光动力效应，注射给药后能在癌症部位靶向聚集，在近红外光的照射下温度升高，在利用光动力效应杀死癌细胞的同时温度升高促使药物在癌症部位有效释放。这种化学药物靶向疗法与光动力学靶向疗法的协同作用可以更有效的杀死癌细胞来治疗癌症。 2、红细胞膜仿生递药系统成熟的红细胞内没有细胞核和细胞器，方便提取和纯化细胞膜，为细胞膜仿生纳米粒的首选膜材料。红细胞膜表面的 CD47 跨膜蛋白可与抑制性受体调节蛋白 SIRPα 结合并发出抑制免疫细胞吞噬红细胞的信号，因而机体会误认为表面涂覆红细胞膜的载药纳米粒子是自身成分，进而免受巨噬细胞的吞噬，实现血液长循环。近年来，以红细胞膜涂覆在纳米粒子上制备的细胞膜仿生纳米递药系统已有大量研究。研究表明，红细胞膜仿生纳米粒在增强血液循环方面明显优于 PEG 修饰纳米粒，PEG 修饰纳米粒子重复给药后容易诱导免疫应答反应产生抗 PEG IgM和IgG 抗体，导致其血液清除加速循环时间越来越短。与之相比，红细胞膜仿生纳米粒在多次注射后不会导致IgM 或 IgG抗体的增加，因此红细胞膜仿生纳米粒在多次注射后其长循环时间是一致的。肿瘤靶向肽修饰的红细胞膜仿生纳米系统具有较高的载药量，在体内表现为良好的靶向性，生物相容性，同时可延长保留时间。与非靶向药物制剂相比，此类纳米颗粒具有红细胞和肽的特性，具有显著的疗效，同时明显降低毒性。除了化学治疗外，基于红细胞膜的药物递送系统已迅速扩展到其他肿瘤治疗方法，包括光动力疗法( PDT) 、光热疗法( PTT) 和免疫疗法。利用红细胞独特的天然携氧能力，红细胞膜可以改善光动力治疗中缺氧的问题。研究发现，由红细胞膜和光敏剂( PS) 组成的红细胞膜微型电动机可以有效靶向肿瘤组织，同时提供大量的氧气。另一种有效的设计是通过将红细胞膜包被在二氧化锰纳米颗粒上形成氧气前体，以产生氧气并缓解肿瘤缺氧。红细胞膜包被增加了阿霉素的负载能力，同时由于产生的氧气破坏红细胞膜而加速了阿霉素的释放。通过结合普鲁士蓝，可以实现PTT和化学疗法的联合治疗。 3、血小板膜仿生递药系统研究表明，血小板在癌变中起着至关重要的作用。在肿瘤进展过程中发生的炎症会使血小板回到肿瘤部位，刺激肿瘤血管生成。此外，血小板维持肿瘤细胞外渗和循环肿瘤细胞在血液中的存活，血小板与循环血液中肿瘤细胞的相互识别和相互作用与肿瘤转移关系密切。循环血液中肿瘤细胞CD44 过表达，血小板上 p-选择素可以与 CD44 受体结合，使血小板聚集于循环血液中的肿瘤细胞，有助于其在血液中的生存并转移至新的组织从而有利于转移扩散。基于血小板与肿瘤细胞之间的相互作用，有学者利用 RGD 肽修饰的血小板囊泡对载有阿霉素的纳米粒子进行包裹，合成了血小板伪装纳米载药囊泡，实现了对肿瘤细胞和肿瘤血管的双重靶向，有效抑制了耐药肿瘤的生长。血小板膜包被的纳米粒还可用于肿瘤成像，研究报道了一种血小板膜包被的磁性纳米粒用于增强癌症成像和治疗，将从小鼠血液中收集的血小板膜涂覆在 Fe3O4 磁性纳米粒上，结果显示，该治疗诊断系统可用于增强肿瘤磁共振成像和光动力学疗法，对于癌症的个性化诊断和治疗具有潜在应用价值。血小板膜仿生纳米载体具有生物相容性好、免疫原性低和靶向性强等优点，但其平均寿命短以及原材料的获取和来源的问题，严重限制了其走向规模化和临床化的进程。通过将红细胞膜与血小板膜融合来制备复合膜纳米载体，同时结合了两种细胞的生物学功能：具有血小板的肿瘤靶向性和红细胞的长半衰期，为复合细胞膜仿生纳米粒子的发展提供了新思路。 4、白细胞膜仿生递药系统白细胞在血液中天然存在，其数量可因每日不同时间、机体的功能状态而在一定范围内变化。白细胞具有较强的移动能力，可从血管内迁移到血管外，也可从血管外组织迁移到血管内。因此，白细胞也广泛存在于血管、淋巴管以外的机体组织中。白细胞主要功能是为机体起到防御的作用，可识别体外来源的细菌、病毒等，主要包括巨噬细胞、粒细胞和淋巴细胞。各种白细胞对异常细胞和组织均有免疫应答响应，因此白细胞膜仿生递药系统用于靶向递送药物的研究也逐渐成为热点。研究证实，包被巨噬细胞膜的纳米粒可以显示出与包被红细胞膜的纳米粒类似的血液长循环时间，巨噬细胞膜仿生纳米粒子可以通过保留在膜上的功能蛋白对肿瘤细胞具有跨越血管屏障和分子识别的能力。通过纳米粒子和细胞膜之间的静电和疏水相互作用将巨噬细胞膜涂覆到二氧化硅纳米粒表面，研究发现纳米粒表面的膜功能蛋白可有效防止巨噬细胞或静脉内皮细胞对纳米粒的摄取，并与肿瘤炎症的内皮细胞结合从而靶向的运输药物，与未包被巨噬细胞膜的纳米载体相比，巨噬细胞膜包被的纳米载体具有突出的肿瘤靶向性和归巢效应。有学者将中性粒细胞膜涂覆在卡非佐米的纳米粒表面，用于癌症转移的预防和治疗。研究表明，中性粒细胞膜仿生的载药纳米粒子可以对血液中的循环肿瘤细胞进行精准定位、靶向给药，促进循环肿瘤细胞的凋亡，减少血行传播的机会，阻止早期肿瘤结节的形成。免疫细胞膜仿生技术有很好的应用前景，但仍有一定的局限性。由于免疫细胞的炎症趋化性特性，该递药系统有可能在非癌症炎性部位聚集产生错靶效应，另外，免疫细胞趋化性和外渗过程非常复杂，而免疫细胞膜仿生的载药纳米粒子不是活细胞，几乎不可能维持免疫细胞的所有复杂功能。参考资料 [1]张强,罗曦,包永睿等.生物膜仿生纳米制剂研究进展[J/OL].中国药科大学学报:1-15[2023-11-01]. [2]黄领领，吴宏辉，许东航等.细胞膜仿生纳米技术在肿瘤靶向递药系统中的研究进展[J].药学学报，2022，57(01):85-97+276. [3]石雯，胡芳芳，尹铁英，王亚洲.细胞膜仿生修饰纳米粒肿瘤治疗的研究进展[J].生物化学与生物物理进展，2022，(第3期). [4]贾洪鑫，张岩.细胞膜仿生纳米递药系统在肿瘤治疗中的研究进展[J].中国科技期刊数据库(医药)，2021，(第3期). 作者简介：小米虫，药品质量研究工作者，长期致力于药品质量研究及药品分析方法验证工作，现就职于国内某大型药物研发公司，从事药品检验分析及分析方法验证。来源：CPHI制药在线声明：本文仅代表作者观点，并不代表制药在线立场。本网站内容仅出于传递更多信息之目的。如需转载，请务必注明文章来源和作者。投稿邮箱：Kelly.Xiao@imsinoexpo.com▼更多制药资讯，请关注CPHI制药在线▼点击阅读原文，进入智药研习社~

放射疗法

2023-09-14

·Science Daily

Researchers make strides in harnessing low-grade heat for efficient energy conversion

A research team has achieved significant breakthroughs in harnessing low-grade heat sources (<100 °C) for efficient energy conversion. A team of researchers, jointly led by Professor Hyun-Wook Lee and Professor Dong-Hwa Seo from the School of Energy and Chemical Engineering at the Ulsan National Institute of Science and Technology (UNIST), in collaboration with Professor Seok Woo Lee from Nanyang Technological University in Singapore, has achieved significant breakthroughs in harnessing low-grade heat sources (<100 °C) for efficient energy conversion. Their groundbreaking work focuses on developing a highly efficient Thermally Regenerative Electrochemical Cycle (TREC) system capable of converting small temperature differences into usable energy. Conventional energy-harvesting systems face challenges when it comes to effectively utilizing low-grade heat sources. However, TREC systems offer an attractive solution as they integrate battery functionality with thermal-energy-harvesting capabilities. In this study, the research team delved into the role of structural vibration modes to enhance the efficacy of TREC systems. By analyzing how changes in covalent bonding influence vibration modes -- specifically affecting structural water molecules -- the researchers discovered that even minute amounts of water induce strong structural vibrations within cyanide ligands' A1g stretching mode. These vibrations substantially contribute to a larger temperature coefficient (ɑ) within a TREC system. Based on these insights, the team designed and implemented a highly efficient TREC system using a sodium-ion-based aqueous electrolyte. "This study provides valuable insights into how structural vibration modes can enhance the energy-harvesting capabilities of TREC systems," explained Professor Hyun-Wook Lee. "Our findings deepen our understanding of Prussian Blue analogs' intrinsic properties regulated by these vibration modes -- opening up new possibilities for improved energy conversion." The potential applications for TREC systems are vast, particularly in wearable technologies and other devices where small temperature differentials exist. By effectively capturing and converting low-grade heat into usable energy, TREC systems offer a promising pathway towards the development of next-generation secondary batteries. The study findings have been published ahead of their official publication in the online version of Advanced Materials on July 3, 2023. This research has received support from the 2023 Research Fund of UNIST, Individual Basic Science & Engineering Research Program, and the National Center for Materials Research Data through the National Research Foundation (NRF) of Korea, funded by the Ministry of Science and ICT (MSIT).

100 项与普鲁士蓝相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	普鲁士蓝	V03AB31	DB06783

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
重金属中毒	美国	H e y l Chemisch-pharmazeutische Fabrik GmbH & Co. KG	2003-10-02

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


SNMMI2021	N/A	-	-	Prussian Blue Nanoparticles (BC-PB composite)	夢淵鑰蓋鑰糧獵繭築夢(積鏇觸構獵網鏇壓鏇憲) = 艱鹽製蓋餘選鏇積衊襯憲鬱憲夢窪構製築膚廠 (憲蓋艱糧鹽襯糧遞繭鑰 ) 更多	-	2021-05-18
				Prussian Blue Nanoparticles (PB NPs)	夢淵鑰蓋鑰糧獵繭築夢(積鏇觸構獵網鏇壓鏇憲) = 壓淵製窪積衊膚壓簾網憲鬱憲夢窪構製築膚廠 (憲蓋艱糧鹽襯糧遞繭鑰 )